Cellectar Biosciences Inc., of Madison, Wis., said the FDA accepted its investigational new drug application to begin clinical trials of I-131-CLR1404, a highly selective, cancer-targeting radiopharmaceutical, in patients with relapsed or refractory multiple myeloma.